The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Between the 1960s and the 2010s, the percentage of children living with their married parents in their first marriage declined from approximately three quarters to just under half. At the same time, the share of children raised by single parents rose sharply. During the 2000s and 2010s, the number of American children raised by their grandparents or other family members rather than their parents also grew. American parents of the early twenty-first century usually do not insist that their children share the same political or religious beliefs, to follow the same traditions, or to get married and have children. Rather, they emphasize ethical behavior, tolerance, generosity, and financial independence. Parents from wealthier backgrounds are less likely to have children out of wedlock and more likely to stay married, with desirable outcomes for their children, including better social and cognitive development and educational attainment. By contrast, children born into the middle class or the lower class are less likely to have married parents than before. They also tend to have younger parents who did not intend to have them and more siblings. Upper middle-class and wealthy American couples living in the cities tend to have fewer children and to invest heavily in their children in the form of breastfeeding for at least a year, giving them premium healthcare plans, sending them to private schools, and letting them eat organic foods.
=== Herchel Smith Laboratory for Medicinal Chemistry === The Herchel Smith Laboratory for Medicinal Chemistry is a laboratory under the aegis of the Regius Professor of Physic in the School of Clinical Medicine.
== Symbols and units == The IUPAC-recommended symbols for mass and charge are m and Q, respectively, however using a lowercase q for charge is also very common. Charge is a scalar property, meaning that it can be either positive (+) or negative (−). The Coulomb (C) is the SI unit of charge; however, other units can be used, such as expressing charge in terms of the elementary charge (e). The SI unit of the physical quantity m/Q is kilogram per coulomb.
The nitrates are used for the treatment and prevention of angina and acute myocardial infarction, while molsidomine acts too slowly to be useful for the treatment of acute angina. For quick action in the treatment of angina, glyceryl trinitrate is used in form of a sublingual spray (nitro spray) or as soft capsules to be crunched. Nitroprusside is used intravenously for the treatment of hypertensive crises, heart failure, and lowering of blood pressure during surgery.
=== Approval of discoveries === In December 2015, the conclusions of a new JWP report were published by IUPAC in a press release, in which element 113 was awarded to Riken; elements 115, 117, and 118 were awarded to the collaborations involving the JINR. A joint 2016 announcement by IUPAC and IUPAP had been scheduled to coincide with the publication of the JWP reports, but IUPAC alone decided on an early release because the news of Riken being awarded credit for element 113 had been leaked to Japanese newspapers. For the first time in history, a team of Asian physicists would name a new element. The JINR considered the awarding of element 113 to Riken unexpected, citing their own 2003 production of elements 115 and 113, and pointing to the precedents of elements 103, 104, and 105 where IUPAC had awarded joint credit to the JINR and LBNL. They stated that they respected IUPAC's decision, but reserved determination of their position for the official publication of the JWP reports. The full JWP reports were published on 21 January 2016. The JWP recognised the discovery of element 113, assigning priority to Riken. They noted that while the individual decay energies of each nuclide in the decay chain of 278113 were inconsistent, their sum was now confirmed to be consistent, strongly suggesting that the initial and final states in 278113 and its daughter 262Db were the same for all three events. The decay of 262Db to 258Lr and 254Md was previously known, firmly anchoring the decay chain of 278113 to known regions of the chart of nuclides.
Sources: en.wikipedia.org
The submucosa (tela submucosa), or submucosal layer, is a thin layer of tissue in various organs of the gastrointestinal, respiratory, and genitourinary tracts. It is the layer of dense irregular connective tissue that supports the mucosa (mucous membrane) and joins it to the muscular layer, the bulk of overlying smooth muscle (fibers running circularly within layer of longitudinal muscle). The submucosa (sub- + mucosa) is to a mucous membrane what the subserosa (sub- + serosa) is to a serous membrane.
=== Organic nitrogen compounds === Nitrogen is one of the most important elements in organic chemistry. Many organic functional groups involve a carbon–nitrogen bond, such as amides (RCONR2), amines (R3N), imines (RC(=NR)R), imides (RCO)2NR, azides (RN3), azo compounds (RN2R), cyanates (ROCN), isocyanates (RNCO), nitrates (RONO2), nitriles (RCN), isonitriles (RNC), nitrites (RONO), nitro compounds (RNO2), nitroso compounds (RNO), oximes (RC(=NOH)R), and pyridine derivatives. C–N bonds are strongly polarised towards nitrogen. In these compounds, nitrogen is usually trivalent (though it can be tetravalent in quaternary ammonium salts, R4N+), with a lone pair that can confer basicity on the compound by being coordinated to a proton. This may be offset by other factors: for example, amides are not basic because the lone pair is delocalised into a double bond (though they may act as bases at very low pH, being protonated at the oxygen), and pyrrole is not basic because the lone pair is delocalised as part of an aromatic ring. The amount of nitrogen in a chemical substance can be determined by the Kjeldahl method. In particular, nitrogen is an essential component of nucleic acids, amino acids and thus proteins, and the energy-carrying molecule adenosine triphosphate and is thus vital to all life on Earth.
=== Cuban Thaw and attempts to repair relationship === In 2011, Lazaro Cuesta Valdes was elected as the Grand Commander of the Supreme Council of Cuba. After his election, the Supreme Council created a Facebook page, launched an updated webpage, and launched the first International Conference on Freemasonry and Integration to Current Society. Between 2012 and 2014, Grand Commander Cuesta Valdes travelled around the world, first to Rome, and then to visit the Supreme Councils of the United States' Southern Jurisdiction and Northern Jurisdiction, in Ohio and Washington, D.C. Informally, he also met with leaders of the Cuban exile Freemasonry community in Miami to strengthen relations with the United States. In October 2013, the Supreme Council of Cuba held an open meeting and invited Cuban Masons living anywhere to Havana to discuss the fractured state of Cuban Freemasonry. Grand Master Gutierrez Torres attended and drafted Official Message No. 6 after discussions with members of the diaspora. In April 2014, while still in prison, Alan Gross launched a hunger strike to protest his treatment by both Cuba and the United States. When the Associated Press leaked the ZunZuneo program documents to the public, Senator Patrick Leahy called it: "Dumb, dumb, dumb." Leahy then led the Senate committee review of the debacle. On December 17, 2014, Alan Gross was released from Cuban prison in exchange for three members of the Cuban Five, who had been detained in the United States and charged with espionage. On December 10, 2016, the Lazaro F.
====== Pain medicine ====== To train in the add-on specialty of pain medicine a physician must first be a specialist in one of the pediatric class specialties, one of the independent class specialties (excluding clinical pharmacology, clinical genetics, forensic medicine, and social medicine), one of the internal medicine class specialties, one of the surgical class specialties, one of the neurological class specialties (excluding clinical neurophysiology) or one of the psychiatric class specialties.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.